Price
$0.93
Decreased by -1.06%
Dollar Volume
267.82 K
ADR%
9.57
Earnings Report Date (estimate)
Mar 15, 23 (-0.47)
Market Cap.
40.71 M
Shares Float
31.74 M
Shares Outstanding
43.77 M
Beta
1.69
Price / Earnings
-0.33
BPR
219.40
20D Range
0.75 1.00
50D Range
0.67 1.00
200D Range
0.56 1.14
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 8, 22 -0.52
Increased by +30.67%
-0.55
Increased by +5.45%
Aug 9, 22 -0.64
Increased by +13.51%
-0.57
Decreased by -12.28%
May 10, 22 -0.68
Decreased by -4.62%
-0.59
Decreased by -15.25%
Mar 17, 22 -0.65
Increased by +10.96%
-0.74
Increased by +12.16%
Nov 4, 21 -0.75
Increased by +25.74%
-0.76
Increased by +1.32%
Aug 5, 21 -0.74
Increased by +7.50%
-0.67
Decreased by -10.45%
May 13, 21 -0.65
Increased by +15.58%
-0.77
Increased by +15.58%
Mar 18, 21 -0.73
Decreased by -1.39%
-0.90
Increased by +18.89%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
0.00
Increased by +100.00%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-28.05 M
Increased by +10.62%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-29.83 M
Decreased by -10.91%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-28.23 M
Decreased by -0.34%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-32.61 M
Increased by +11.33%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-31.39 M
Decreased by -8.88%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-26.90 M
Decreased by -3.57%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-28.13 M
Decreased by -24.13%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.